Tiziana Life Sciences Ltd

NasdaqCM:TLSA

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United Kingdom

Market Cap

USD 204.48 M

Share Price

USD 1.75

Avg Daily Volume

465,777

Change (1 day)

10.76%

Change (1 year)

80.41%

Change (YTD)

151.36%

Tiziana Life Sciences Ltd Receivables for the year ending December 31, 2023

Tiziana Life Sciences Ltd Receivables is NA for the year ending December 31, 2023. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Receivables	Inventory	Current Assets	Property, Plant, Equipment (Net)

NasdaqCM: TLSA

Tiziana Life Sciences Ltd

CEO	Dr. Ivor R. Elrifi Ph.D.
IPO Date	Nov. 20, 2018
Location	United Kingdom
Headquarters	55 Park Lane
Employees	9
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.